173 related articles for article (PubMed ID: 37103889)
1. Budesonide delayed-release capsules to reduce proteinuria in adults with primary immunoglobulin A nephropathy.
Barratt J; Lafayette RA; Rovin BH; Fellström B
Expert Rev Clin Immunol; 2023; 19(7):699-710. PubMed ID: 37103889
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial.
Lafayette R; Kristensen J; Stone A; Floege J; Tesař V; Trimarchi H; Zhang H; Eren N; Paliege A; Reich HN; Rovin BH; Barratt J;
Lancet; 2023 Sep; 402(10405):859-870. PubMed ID: 37591292
[TBL] [Abstract][Full Text] [Related]
3. Enteric-Coated Capsules Providing Reliable Site-Specific Drug Delivery to the Distal Ileum.
Grimm M; Großmann L; Senekowitsch S; Rump A; Polli JE; Dressman J; Weitschies W
Mol Pharm; 2024 Jun; 21(6):2828-2837. PubMed ID: 38723178
[TBL] [Abstract][Full Text] [Related]
4. Budesonide versus systemic corticosteroids in IgA Nephropathy: A retrospective, propensity-matched comparison.
Ismail G; Obrişcă B; Jurubiţă R; Andronesi A; Sorohan B; Vornicu A; Sinescu I; Hârza M
Medicine (Baltimore); 2020 Jun; 99(26):e21000. PubMed ID: 32590815
[TBL] [Abstract][Full Text] [Related]
5. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial.
Fellström BC; Barratt J; Cook H; Coppo R; Feehally J; de Fijter JW; Floege J; Hetzel G; Jardine AG; Locatelli F; Maes BD; Mercer A; Ortiz F; Praga M; Sørensen SS; Tesar V; Del Vecchio L;
Lancet; 2017 May; 389(10084):2117-2127. PubMed ID: 28363480
[TBL] [Abstract][Full Text] [Related]
6. The Gut-Renal Connection in IgA Nephropathy.
Coppo R
Semin Nephrol; 2018 Sep; 38(5):504-512. PubMed ID: 30177022
[TBL] [Abstract][Full Text] [Related]
7. Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy.
Barratt J; Lafayette R; Kristensen J; Stone A; Cattran D; Floege J; Tesar V; Trimarchi H; Zhang H; Eren N; Paliege A; Rovin BH;
Kidney Int; 2023 Feb; 103(2):391-402. PubMed ID: 36270561
[TBL] [Abstract][Full Text] [Related]
8. Biomarkers and targeted new therapies for IgA nephropathy.
Coppo R
Pediatr Nephrol; 2017 May; 32(5):725-731. PubMed ID: 27324471
[TBL] [Abstract][Full Text] [Related]
9. A disease-modifying approach to the treatment of IgA nephropathy targeting mucosal IgA synthesis and beyond.
Coppo R
Kidney Int; 2023 Feb; 103(2):258-261. PubMed ID: 36681455
[TBL] [Abstract][Full Text] [Related]
10. Current knowledge of targeted-release budesonide in immunoglobulin A nephropathy: A comprehensive review.
Liao J; Zhou Y; Xu X; Huang K; Chen P; Wu Y; Jin B; Hu Q; Chen G; Zhao S
Front Immunol; 2022; 13():926517. PubMed ID: 36685528
[TBL] [Abstract][Full Text] [Related]
11. Delayed-Release Budesonide in a Patient With Progressive IgA Nephropathy and Stage 4 Chronic Kidney Disease: A Case Report.
Gholizadeh Ghozloujeh Z; Srinivasan V; Al Jurdi A; Abdipour A; Norouzi S
J Investig Med High Impact Case Rep; 2024; 12():23247096241260964. PubMed ID: 38869105
[TBL] [Abstract][Full Text] [Related]
12. A pediatric case of IgA nephropathy benefitting from targeted release formulation-budesonide.
Antonucci L; Colucci M; Emma F; Vivarelli M
Pediatr Nephrol; 2023 Nov; 38(11):3849-3852. PubMed ID: 37041389
[TBL] [Abstract][Full Text] [Related]
13. Clinical Significance of Galactose-Deficient IgA1 by KM55 in Patients with IgA Nephropathy.
Zhang K; Li Q; Zhang Y; Shang W; Wei L; Li H; Gao S; Yan T; Jia J; Liu Y; Lin S
Kidney Blood Press Res; 2019; 44(5):1196-1206. PubMed ID: 31574506
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of serum and mesangial galactose-deficient IgA1 in patients with IgA nephropathy.
Wada Y; Matsumoto K; Suzuki T; Saito T; Kanazawa N; Tachibana S; Iseri K; Sugiyama M; Iyoda M; Shibata T
PLoS One; 2018; 13(11):e0206865. PubMed ID: 30388165
[TBL] [Abstract][Full Text] [Related]
15. Associations of ABO blood type and galactose-deficient immunoglobulin A1 with adverse outcomes in patients with IgA nephropathy.
Wang M; Lv J; Chen P; Yu G; Shi S; Liu L; Zhou X; Xu D; Zhao M; Zhang H
Nephrol Dial Transplant; 2021 Jan; 36(2):288-294. PubMed ID: 31603230
[TBL] [Abstract][Full Text] [Related]
16. Sialylation of IgG inhibits the formation of galactose-deficient IgA1-containing immune complexes and protects mesangial cells from injury in IgA nephropathy.
Liu Y; Li H; Yu H; Wang F; Jia J; Yan T
BMC Nephrol; 2022 Jan; 23(1):25. PubMed ID: 35016642
[TBL] [Abstract][Full Text] [Related]
17. [IgA nephropathy].
Floege J
Urologie; 2024 Jan; 63(1):103-111. PubMed ID: 38170257
[TBL] [Abstract][Full Text] [Related]
18. Immunostaining of galactose-deficient IgA1 by KM55 is not specific for immunoglobulin A nephropathy.
Zhao L; Peng L; Yang D; Chen S; Lan Z; Zhu X; Yuan S; Chen G; Liu Y; Liu H
Clin Immunol; 2020 Aug; 217():108483. PubMed ID: 32479989
[TBL] [Abstract][Full Text] [Related]
19. Galactose-Deficient IgA1 B cells in the Circulation of IgA Nephropathy Patients Carry Preferentially Lambda Light Chains and Mucosal Homing Receptors.
Zachova K; Jemelkova J; Kosztyu P; Ohyama Y; Takahashi K; Zadrazil J; Orsag J; Matousovic K; Galuszkova D; Petejova N; Mestecky J; Raska M
J Am Soc Nephrol; 2022 May; 33(5):908-917. PubMed ID: 35115327
[TBL] [Abstract][Full Text] [Related]
20. Immunostaining for galactose-deficient immunoglobulin A is not specific for primary immunoglobulin A nephropathy.
Cassol CA; Bott C; Nadasdy GM; Alberton V; Malvar A; Nagaraja HN; Nadasdy T; Rovin BH; Satoskar AA
Nephrol Dial Transplant; 2020 Dec; 35(12):2123-2129. PubMed ID: 31369128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
